22 July 2022
Haleon plc
Haleon announces appointment of joint corporate brokers
Haleon plc, a global leader in consumer health, is pleased to announce the appointment of Citigroup Global Markets Limited and UBS as its joint corporate brokers, with immediate effect.
ENDS
About Haleon
Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. The group employs over 22,000 people across 170 markets, who are united by Haleon's purpose - to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com
Contact Details
|
Investor Relations |
Media Relations |
||
|
Sonya Ghobrial |
+44 (0) 7392 784784 |
Nidaa Lone |
+44 (0) 7841 400607 |
|
Emma White |
+44 (0) 7823 523562 |
Ross Whittam |
+44 (0) 7796 204198 |
|
Rakesh Patel |
+44 (0) 7552 484646 |
||